Single oral dose of cefaclor for the treatment of infections with penicillinase-producing strains of Neisseria gonorrhoeae.
A single oral dose of 3 g cefaclor was effective in the treatment of uncomplicated gonococcal infection in women due to penicillinase-producing strains of Neisseria gonorrhoeae (PPNG). Cefaclor was equally active in vitro against both PPNG (MIC range, 0.01-1.0 microgram/ml) and non-PPNG strains (MIC range, 0.005-2.0 micrograms/ml). As empirical treatment cefaclor was effective in 53 of 57 (93%) patients compared with ampicillin, to which only 37 of 53 (69.8%) patients responded. This difference was attributed to the 40% incidence of PPNG in the patients studied; as expected, such patients responded poorly to ampicillin.
D000293:Adolescent; D000328:Adult; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D002433:Cefaclor / Q000494:pharmacology / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D009344:Neisseria gonorrhoeae / Q000187:drug effects / Q000201:enzymology; D010405:Penicillinase / Q000096:biosynthesis
D002433:Cefaclor; D000667:Ampicillin; D010405:Penicillinase; D002506:Cephalexin